Stem Cell-Mediated Regeneration of the Adult Brain by Jessberger, Sebastian
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Stem Cell-Mediated Regeneration of the Adult Brain
Jessberger, Sebastian
DOI: https://doi.org/10.1159/000447646
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-133805
Published Version
Originally published at:
Jessberger, Sebastian (2016). Stem Cell-Mediated Regeneration of the Adult Brain. Transfusion Medicine
and Hemotherapy, 43(5):321-326.
DOI: https://doi.org/10.1159/000447646
Fax +49 761 4 52 07 14
Information@Karger.com
www.karger.com
Accessible online at: 
www.karger.com/tmh
Review Article
Transfus Med Hemother 2016;43:321–326
DOI: 10.1159/000447646
Stem Cell-Mediated Regeneration of the Adult Brain
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brain upon injury [2, 3]. However, even the human brain holds 
substantial potential for at least partial compensation and thus 
functional repair by a process called functional neuroplasticity: for 
example, motor or sensory skills that are lost in the course of an 
ischemic stroke can be – with time and training – taken over by 
other brain regions that had not been involved in those motor or 
sensory functions before the injury [4]. 
But even though injury-induced functional regeneration and 
compensation can have a substantial impact on life quality, it often 
fails to allow for an acceptable level of functionality leaving pa-
tients suffering acute or chronic injury with severe disabilities. 
Thus, strategies need to be developed that aim to support the 
brain’s attempts to regenerate. In principle, three different ap-
proaches have been pursued over the last decades. In the following, 
we will review the main approaches that are designed to improve 
functional regeneration of the injured brain and that are based on 
i) activation and recruitment of endogenous neural stem cells 
(NSCs), ii) reprogramming of neural cells for tailored cell replace-
ment therapies, and iii) exogenous transplantation-based ap-
proaches (fig. 1). Finally, we discuss potential next steps to move 
forward innovative regenerative approaches for brain repair be-
cause, despite substantial advances in the last years, the vast major-
ity of potential therapies are currently far from being used in the 
clinical routine. 
Harnessing Endogenous Neural Stem Cells for Brain 
Repair
It has been a longstanding dogma in the neurosciences that all 
neurons in the mammalian brain are generated during embryonic 
and early postnatal neurogenesis. However, first evidence generate 
in the mid-1960s suggested that even in the adult brain new neu-
rons are generated throughout life in distinct regions [5]. However, 
it took almost another 30 years and the advancement of technical 
approaches such as the thymidine analogue BrdU and confocal mi-
croscopy to unambiguously show that i) a cell is newborn in the 
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Summary
Acute or chronic injury of the adult mammalian brain is 
often associated with persistent functional deficits as its 
potential for regeneration and capacity to rebuild lost 
neural structures is limited. However, the discovery that 
neural stem cells (NSCs) persist throughout life in dis-
crete regions of the brain, novel approaches to induce 
the formation of neuronal and glial cells, and recently 
developed strategies to generate tissue for exogenous 
cell replacement strategies opened novel perspectives 
how to regenerate the adult brain. Here, we will review 
recently developed approaches for brain repair and dis-
cuss future perspectives that may eventually allow for 
developing novel treatment strategies in acute and 
chronic brain injury. 
© 2016 S. Karger GmbH, Freiburg
Introduction 
The brain is at constant risk to be hurt and impaired in its func-
tion by traumatic injuries or chronic diseases, associated with in-
flammation and neurodegeneration. In contrast to many other or-
gans and tissues such as the skin or liver in mammals that retain 
the capacity to regenerate and regain at least partially lost func-
tions, the brain cannot simply regrow injured areas that become 
functionally connected to the unharmed regions of the brain [1]. 
The inability of the mammalian brain to regenerate has been asso-
ciated with its complex functions and the required need for stabil-
ity, which is in contrast to lower species such as certain inverte-
brates that retain the capacity to regrow substantial parts of the 
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adult brain and ii) differentiates into a neuron [6]. It is now fully 
accepted that new neurons are generated throughout life in mam-
mals [7]. 
However, there seem to be substantial species differences: 
whereas in rodents (and also non-human primates) a substantial 
number of NSCs persist in the subventricular zone (SVZ) that gen-
erate new cells migrating via the rostral migratory stream (RMS) 
towards the olfactory bulb (OB) where they differentiate into differ-
ent types of olfactory neurons, this neurogenic system seems to be 
absent/inactive in the adult human brain [8–11]; but see also [12]. 
In contrast, new neurons are born throughout life in the hippocam-
pal dentate gyrus (DG) both in rodents and primates including hu-
mans [13–15]. The hippocampus is required for certain forms of 
learning and in simple terms serves as a filter station that is required 
for many types of memory and determines which of these memo-
ries are transferred into long-term storage [16]. Furthermore, the 
hippocampus is involved in the regulation of mood [17]. 
In the DG, NSCs reside in the subgranular zone where they di-
vide and generate cells that differentiate into excitatory, glutamater-
gic granule cells and that integrate into the DG over the course of 
several weeks [18, 19]. This process, called adult hippocampal neu-
rogenesis, is important for proper hippocampal function and criti-
cally involved in dentate computation of incoming information 
[20–22]. Thus, the main purpose of neurogenesis in the DG is cer-
tainly not to serve as a backup system for repair in the case of  injury. 
Neurogenesis is required for normal brain function. 
However, failing or altered neurogenesis has been associated 
with several neuropsychiatric diseases. For example, it has been 
shown that stress, one of the key components in the etiology of 
 affective disorders, substantially decreases the number of newborn 
neurons [23]. Furthermore, it has been shown that certain antide-
pressants such as selective serotonin-reuptake inhibitor (SSRI; e.g., 
fluoxetine) enhance neurogenesis and require proper neurogenesis 
for their antidepressant action, at least in rodents [24–26]. Thus, 
altered neurogenesis may participate in the disease process of affec-
tive disorders such as major depression. Given this, novel com-
pounds that specifically target the activity of NSCs or later steps of 
neuronal differentiation/integration may have beneficial effects in 
the treatment of affective disorders. 
However, neurogenesis cannot only be reduced, but there are 
also circumstances where the integration of newborn granule cells is 
affected: epileptic seizures induce the ectopic generation of granule 
cells that do not show proper integration into the DG circuit [27, 
28]. They extend aberrant processes and show aberrant migration, 
for example into the hilus of the DG. Thus, it has been speculated 
that seizure-induced, aberrant neurogenesis may interfere with 
proper circuit function in epilepsy patients and may also contribute 
to the process of epileptogenesis [29]. Targeting NSCs and the neu-
rogenic process in depression or epilepsy may hold the potential to 
ameliorate disease symptoms or to attenuate disease progression. 
Normalizing or enhancing neurogenesis in the context of dis-
eases affecting this process is only one aspect how the neurogenic 
permissiveness of adult NSCs may be useful to ameliorate brain 
function. Clearly, the finding that NSCs persist in the adult brain 
has also opened new possibilities for targeted induction of neuro-
genesis in the adult brain. When can this be helpful? Many degen-
erative diseases of the nervous system are associated with substan-
tial neuronal cell death in the chronic phase of the disease although 
neural death and degeneration also affects early and subclinical 
phases of many brain diseases. Even though novel treatment op-
Fig. 1. Enhancing 
brain repair and regen-
eration. Shown are three 
main aspects how regen-
eration of adult brain 
may be achieved in the 
future. This may become 
possible by enhancing 
the activity of endoge-
nous NSCs to generate 
neurons, for example by 
using compounds that 
enhance the formation 
of new neurons. Further, 
the ectopic generation of 
neurons (or glial cells 
such as myelinating oli-
godendrocytes) outside 
the neurogenic niches 
may be achieved by ex-
pression of transcription 
factors inducing fate 
changes such as SOX2 
and Ascl1. Furthermore, 
the development of novel cell sources may improve the benefits of studies based on the transplantation of neural cells to replace lost tissue where the aim is to either 
transplant stem cells or their differentiated progeny to enhance brain repair. For details please refer to the main text. 
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tions appear on the horizon that for example attenuate disease pro-
gression in Alzheimer’s disease (AD) by reducing the amyloid load 
in affected patients [30, 31], it is also clear that neurons that are lost 
at the stage of diagnosis/treatment will be chronically lost. Thus, 
enhancing neurogenesis in diseases such as AD that dramatically 
affect hippocampal function may be useful to improve brain func-
tion by providing new neurons for the injured hippocampus. If en-
hanced neurogenesis is efficient to enhance cognitive function in 
humans remains unclear but is certainly an exciting area where the 
combination of approaches to attenuate disease progression (e.g., 
lowering amyloid load) together with regenerative strategies (i.e., 
enhancing neurogenesis) may turn out to be effective and clinically 
relevant in the future [32]. 
As outlined above, neurogenesis in the SVZ/OB seems to ex-
tremely low or completely absent in the human brain [11]. How-
ever, there is evidence that NSCs may be also retained in the 
human SVZ but that they are just not generating cells that migrate 
to the OB [10, 12, 33]. Interestingly, it has been recently shown that 
neuroblasts are present also in the adult human SVZ and neighbor-
ing striatum and that they are able to generate new striatal in-
terneurons throughout life in the human brain [34]. Strikingly, this 
type of neurogenesis appears to be substantially lower in patients 
with Huntington’s disease (HD), suggesting that approaches to en-
hance striatal neurogenesis may represent a novel therapeutic ap-
proach in HD [34]. Thus, enhancing neurogenesis in the SVZ may 
also hold the potential for repair in the human brain. Basic re-
search in the SVZ aiming to understand how NSCs become acti-
vated may turn out to be helpful to induce neurogenesis also in the 
human SVZ [35]. 
NSCs may not represent the only source for neurons generated 
in the human brain. Whereas in the rodent SVZ NSCs are capable 
to respond to injuries such as ischemic strokes that lesion the 
neighboring striatum resulting in the enhanced generation and 
subsequent striatal migration of new neurons generated in the 
SVZ, strokes in human seem not to directly affect neurogenesis in 
the SVZ [36–38]. However, recent data in mice showed that local 
astroglial cells carry a latent neurogenic program (e.g., being capa-
ble to generate neuronal cells) that becomes activated upon is-
chemic stroke [39]. Mechanistically, the latent neurogenic program 
depends on Notch signaling, providing an entry point how this 
novel route for neurogenesis may also be targeted in human dis-
eases such as stroke [39]. 
Taken together, the finding that NSCs remain active in the adult 
mammalian brain and that new neurons are generated throughout 
life has opened novel approaches to either ameliorate disease 
symptoms or to truly induce neurogenesis in areas where neurons 
are lost in the context of acute or chronic degenerative disease. 
Generating Neuronal and Glial Cells at the Site of 
Injury
Apart from strategies to utilize the neurogenic potential of 
endogenous NSCs to locally generate new neuronal cells, an al-
ternative approach has been to ectopically induce the genera-
tion of neuronal (and glial) cells to support brain repair [40, 
41]. This is based on a vast amount of data from basic research 
aiming to characterize the transcriptional programs that guide 
neurogenesis during embryonic development and in the adult 
neurogenic niches. The idea was to use this knowledge to redi-
rect the fate of newborn cells towards a neuronal fate (or any 
desired cell fate). Thus, key neurogenic transcription factors 
used alone or in combinations with other fate determinants 
have been successfully used in the rodent brain to induce func-
tional neurogenesis, for example after experimental lesions of 
the cortex [42]. Starting cells that were targeted – mostly by ret-
roviral vectors expressing key transcription factors – include 
astroglial (i.e., astrocytes) and oligodendroglial (i.e., oligoden-
drocyte precursors) cells that were directed to generate neurons 
or other required cell types such as oligodendrocytes in the con-
text of demyelinating disease [43–57]. So far the generation of 
several distinct neuronal subtypes has been achieved. This is 
obviously important to replace the exact neuronal subtype that 
is lost in the respective diseases. One example, where neuronal 
cell replacement may turn out to be feasible is Parkinson’s dis-
ease (PD) where mostly dopaminergic neurons are lost. Current 
attempts aim to generate dopaminergic neurons by targeted 
overexpression of single transcription factors or cocktails of 
previously identified key regulators within the striatum (the tar-
get area of most dopaminergic neurons extending their axons) 
or directly in the substantia nigra (where dopaminergic neurons 
are lost in PD) [56, 58]. 
Notably, the tailored generation of cells for brain repair is not 
restricted to neuronal cells. Clearly, a variety of brain diseases are 
associated with a loss of function of glial cells. Of particular inter-
est are oligodendrocytes that form myelin sheets around axons, 
which are required for proper neuronal function. Impaired mye-
lin function and subsequent demyelination is a common feature 
of a variety of diseases ranging from multiple sclerosis (MS) to 
epilepsy [59, 60]. Death of myelinating oligodendrocytes leads ul-
timately to neuronal loss and functional impairments. In the con-
text of MS, immune cells attack myelinating oligodendrocytes 
and subsequently kill them. Whereas the therapeutic possibilities 
and treatment options of the initial inflammatory phase of the 
disease have substantially improved over the last decades, there is 
still no regenerative approach available that may help to induce 
remyelination and thus prevent functional loss that is associated 
with secondary neuronal cell death [59, 61]. Thus, inducing the 
formation of myelinating oligodendrocytes either by activating 
oligodendrocytes precursor cells or by reprogramming other neu-
ral cells into myelinating oligodendrocytes may represent a prom-
ising approach [62, 63]. In this context, it has also been shown 
that NSCs in the DG that do not generate oligodendrocytes under 
normal conditions retain the potential for oligodendrocyte differ-
entiation and can be redirected to adopt an oligodendroglial fate 
[64, 65]. Those newborn oligodendrocytes have at least in animal 
models of demyelinating disease the potential for remyelination 
[66]. 
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Reprogramming cell fate has the exciting potential to tailor cell 
generation depending on the missing cell type. At the same time, 
all those approaches are currently rather invasive (e.g., virus-based 
overexpression of transcription factors) and thus relatively far 
away from clinical applications. But the experimental approaches 
currently tested in animal models of disease may identify novel 
routes how to replace lost neural cells in the human brain. 
Transplantation of Neural Stem Cells and Their 
Progeny to the Injured Brain 
Boosting endogenous NSC activity or targeting neural cells to 
redirect them towards a neuronal fate represent approaches to tar-
get endogenous cell sources for neural cell replacement and repair. 
In addition, the strategy to transplant either neuronal cells or their 
precursors has been investigated over the last decades and has been 
also clinically used [67, 68]. Transplantation-based approaches are 
probably most suitable for diseases in which selected neuronal sub-
types are affected, such as dopaminergic neurons in PD or striatal 
interneurons in HD, and to a lesser extent when more widespread 
degeneration occurs, as for example in AD. In fact, clinical trials 
have been performed for PD in which dopaminergic precursor cells 
were isolated from the fetal mesencephalon followed by transplan-
tation into the diseased brain. However, results were mixed [69–
71]. As it turned out, one of the key factors in predicting the success 
of transplants was the quality and quantity of the transplant. Given 
that the cell source was fetal mesencephalic precursors (derived 
from aborted fetuses), restricting the availability and also contain-
ing progenitors for cells that may have adverse effects upon trans-
plantation (e.g., GABAergic neurons), it became clear that a source 
of transplantable cells that is i) available at large quantities for 
standardization and ii) contains exactly the cell type required (in 
this case dopaminergic neurons/precursors) will be desirable [72]. 
Substantial efforts have been undertaken in the last years to 
generate experimental protocols to yield pure dopaminergic neu-
ronal populations derived from embryonic NSCs or pluripotent 
stem cells such as embryonic stem cells (ESCs) or induced pluripo-
tent stem cells (iPSCs). In fact, there are several promising ap-
proaches identified that at least in non-human primates showed 
exciting results in the context of PD models [58, 73, 74]. At this 
time new clinical trials are prepared that will use novel cell sources 
to test again the feasibility and efficacy of cell transplants to treat 
neurological disease [72]. This is not limited to PD but may also 
turn out to be applicable to other chronic degenerative diseases 
such as HD. 
Perspectives and Conclusions
Regenerating the injured brain to allow for functional recovery 
remains a currently unmet challenge. Even though progress has 
been made in the last decades to ameliorate disease symptoms and 
to slow down disease progression for some diseases, the large ma-
jority of acute or chronic neurodegenerative diseases are still asso-
ciated with substantial functional impairments in the everyday life 
of affected patients. Thus, novel approaches to regenerate the in-
jured adult brain are needed [1]. The finding that NSCs persist in 
the adult brain and that neurogenesis occurs throughout life has 
spurred new hopes that the permissiveness of the adult brain to 
support life-long neurogenesis can be harnessed for repair. In addi-
tion, substantial progress has been made to understand the molec-
ular and cellular mechanisms regulating neuronal differentiation 
and subsequent integration [75]. 
Thus, it is probably realistic to hope that we will be able in the 
future to either recruit endogenous neurogenic cells such as NSCs 
or to reprogram neural cells into neurons. However, a key challenge 
will remain that neurons are not only generated but that they are 
capable to find their proper way into the preexisting circuit allow-
ing for meaningful and correct integration. It is plausible to specu-
late that a wrongly integrated neuron or the wrong neuronal sub-
type may do more harm than improving brain function [76, 77]. 
Even though regional specifics are likely to exist, the adult brain 
gave us with the DG that harbors neurogenic NSCs under physio-
logical conditions a system where we can study neuronal differenti-
ation and integration of newborn neurons that apparently find their 
way into the circuit. In the future, we will have to understand more 
details how new neurons achieve this. These experiments will aim 
to discover more molecular details of adult neurogenesis, but we 
also need improved methods to study the process on a cellular level, 
e.g., using advanced imaging approaches to study the neurogenic 
process directly within the adult mammalian brain. The knowledge 
derived from these experiments will not only be important to de-
velop strategies to recruit/activate endogenous neural cells for cell 
replacement. They will be also important to optimize transplanta-
tion-based approaches with the aim to achieve the best function of 
transplants in the adult brain. However, strategies aiming to trans-
plant exogenous cells for brain repair will require further improved 
and optimized approaches to deliver cells safely and efficiently. 
One apparent problem in the field is the dependence on animal 
models of acute or chronic diseases of the brain. This will not 
change, and in vivo experimental studies will remain a key pillar of 
brain regeneration research. However, the hope is that these ex-
periments will be complemented in the future with approaches 
using human tissues grown in the culture dish that are derived 
from human NSCs or ESCs/iPSCs. Great progress has been made 
over the last years, and it became possible to grow organoids that 
resemble structurally at least early steps of brain development and 
that will allow for testing novel approaches directly in human cells/
tissues [78]. Such organoid-based approaches will need to be 
standardized and improved, but they may represent a novel direc-
tion allowing for faster translation of basic research into human 
treatment strategies. Potential applications are the use of human 
organoids to screen for compounds enhancing NSC activity or re-
directing the fate of newborn cells. In combination with conven-
tional experimental research using animal models of disease, the 
novel tools will hopefully bring us one step closer to achieve sig-
nificant and functional brain regeneration in the future. 
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